Risk of microbial contamination of iodinated contrast media on multiple use of large-volume bottles.

Large-volume bottles of iodinated contrast material (CM) offer advantages over single-dose vials in respect of handling, radiation protection of personnel, cost and waste. Because non-ionic CM are considered to be susceptible to microbial contamination, the probability of such contamination was investigated under practical conditions with reference to the duration of use. Under conditions identical to those in practice, contamination was found in only about 1% of bottles examined after a single piercing.

Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate.

Four nonionic contrast media (iohexol, iopamidol, iopromide, and iosimide) are compared in this clinical study in their pharmacokinetic behavior with an ionic reference preparation (meglumine diatrizoate). At a dose of 1 ml of contrast medium per kilogram of body weight with approximately the same iodine content, virtually no differences could be established in the pharmacokinetic behavior. The osmotic diuresis of the ionic substance, compared with that of the nonionic preparations--implies an increased osmotic diuresis, thus, a lower maximal iodine concentration in the urine.

Urography with monomeric and dimeric nonionic contrast media: comparative, randomized, double-blind study of iotrolan 280 and iopromide 300.

In a double-blind comparative study between the nonionic, dimeric iotrolan and the nonionic, monomeric iopromide the urographic image quality in the dose 300 mg I/kg body weight is better after iopromide up to 20 minutes after the injection. This result appears to be in contradiction to the results of the animal experimental studies. Possible reasons are discussed.

Iopromide dosage and urographic image quality: is there an optimal dose?

The influence of increasing doses of contrast medium (CM; 0.75, 1.0, 1.

[Atresia of the aortic isthmus from the radiological point of view].

The most important angiographic features of atresia of the aortic isthmus are illustrated by three patients. The first patient to have reached an advanced age despite atresia of the aortic isthmus is reported and the diagnosis was confirmed at autopsy. The haemodynamic effects, the age at operation and the incidence of other associated cardiovascular malformations are discussed with reference to the literature.

[Indirect breast lymphography (author's transl)].

Intradermal areolar contrast injection of a new water-soluble contrast medium, Iotasul, results in regular demonstration of the latero-cranial breast lymphatics and of the subareolar lymphatic plexus. It has been possible, for the first time, to show lymph nodes with this water-soluble contrast medium, although the results are not entirely satisfactory. There have been no side effects.

[Sodium salts or methylglucamine salts in contrast media for infusion pyelography? (author's transl)].

Tolerance of two contrast media was compared by a double blind study. High doses of iodine (45 g) were used for both contrast substances. Sodium Ioglicinate was giving best radiological contrast but produced more side-effects, especially nausea, as compared to Methylglucamine-Ioglicinate.

[Sodium or methyl glucamine salts as contrast media for urography (author's transl)].

A double blind trial was carried out comparing 15 g sodium amidotrizoate and 15.3 methyl glucamine amidotrizoate for urography. The sodium preparation resulted in significantly better visualisation of the urinary tract, both in normal patients and in those with renal insufficiency.

[Angiographic appearances of rare renal tumours; oncocytomas and benign hypernephromas (author's transl)].

Oncocytomas, called oxyphil proximal tubular adenomas in the Anglo-Saxon literature, and benign hypernephromas are non-malignant, usually symptomless, rare tumours belonging to the renal adenomas. Oncocytomas have angiographic appearances sufficiently uniform to permit a tentative diagnosis. Histologically benign hypernephromas do not possess characteristic angiographic appearances and, in the presence of tumour in the renal vein or necrotic avascular areas, must be regarded as potentially malignant.

Double blind comparison of meglumine iotroxate (Biliscopin), meglumine iodoxamate (Endobil), and meglumine ioglycamate (Biligram).

Two new intravenous cholegraphic agents, iotroxate and iodoxamate, hold a lower general toxicity, lower protein binding, and claim a higher rate of biliary excretion. Both compounds proved to be equally effective in opacifying the gallbladder and the bile ducts in a double-blind clinical study comprising 400 cases. Iotroxate gave significantly earlier good or adequate visualization as a result of its higher excretion rate by the liver (P less than 0.

[Angiographic findings in benign liver tumours (author's transl)].

Difficulties in the differential diagnosis of benign liver tumours and their differentiation from malignant liver tumours are discussed. Two patients with benign lesions were described, one with a liver cell adenoma, the other with a mixed cholangiohepato-adenoma (local nodular hyperplasia).

[Roentgenologic findings in carcinoma of the prostate (author's transl)].

Discussion of the radiodiagnostic findings in patients with carcinoma of the prostate, especially of tumor changes of prostatic ureterocystography. Lymphography was carried out in 154 patients with carcinoma of the prostate. Lymphnodes metastatic were found more frequently and earlier than skeletal metastases.

[Pharmacokinetics and plasma albumen binding of iotroxic acid (Biliscopin), iodoxic acid (Endomirabil) and ioglycamine (Biligram) (author's transl)].

Pharmacokinetic data after injection of the new cholegraphic contrast medium iotroxic acid (Biliscopin) in man are reported and compared with the results of injections of ioglycamate and iodoxic acid. Iotroxic acid is less completely bound to plasma proteins than ioglycamate, but significancy more so than iodoxamate. Plasma protein binding depends on contrast concentration in the plasma, as does excretion in the urine.

Biotransformation of ioglycamic acid, iodoxamic acid and iotroxic acid in man.

The biotransformation of the 131I-labeled cholegraphic media ioglycamic acid, iodoxamic acid and iotroxic acid in man is investigated. Plasma, urine and fistular bile were analyzed for unchanged and metabolized constituents of the administered substances using thin layer chromatography. No metabolites were found in plasma, but up to two were found in urine in addition to unchanged contrast media (a total of 50% of the total elimination in 24 hr.